KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.

Jan A Burger, Paul M Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers E M Patten, Sebastian Grosicki, Helen McCarthy, Fritz Offner, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, Lynne Neumayr, James P Dean, Paolo Ghia, Thomas J Kipps

Blood 146(18) 2168-2176

PMID40737596
PMCIDPMC12824676
DOI10.1182/blood.2024028205
发表日期2025-07-30
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

With up to 10 years of follow-up, we report results from the final analysis of RESONATE- 2, a phase 3 study of first-line ibrutinib vs chlorambucil for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Patients aged ≥65 years with previously untreated CLL/SLL without del(17p) were randomly assigned to receive either single-agent ibrutinib (420 mg/d; n = 136) or chlorambucil (0.5-0.8 mg/kg; ≤12 cycles; n = 133). With a median follow-up of 9.6 years in the ibrutinib arm, the median progression-free survival (PFS) was 8.9 years (95% confidence interval [CI], 7.0 to not estimable [NE]) vs 1.3 years (95% CI, 0.9-1.6) for the chlorambucil arm. Among patients with unmutated immunoglobulin heavy chain variable (uIGHV), del (11q), mutated TP53, or complex karyotype, the median PFS was 8.4 years (95% CI, 6.8 to NE) with ibrutinib and 0.7 years (95% CI, 0.4-1.2) with chlorambucil. Median overall survival (OS) with ibrutinib was not reached. The most common adverse events (AEs) of any grade included diarrhea (52%), fatigue (41%), cough (39%), nausea (32%), arthralgia (31%), peripheral edema (31%), and hypertension (30%). During the entire study period, 34 of 136 patients (25%) had an ibrutinib dose reduction due to AEs; these AEs improved in 30 of 34 patients (88%). At study completion, 27% of patients remained on first-line ibrutinib treatment. This landmark RESONATE-2 study defines median PFS and demonstrates continued OS benefit of first-line ibrutinib treatment for patients with CLL/SLL, including those with high-risk genomic features. Sustained efficacy and tolerability of ibrutinib reemphasize the favorable benefit-risk profile. This trial was registered at www.ClinicalTrials.gov as NCT01722487/NCT01724346.

KM 提取结果

2 个 Figure · 8 个 KM 面板

进入结果中心
KM Figure4 个面板

Figure 1

Figure 1. Investigator-assessed PFS. (A) All randomly assigned patients. (B) Patients with ≥1 high prognostic risk factor including mutated TP53 , uIGHV, del(11q), and/or CK. (C) Patients with uIGHV or mIGHV. (D) Patients with or without del(11q). CK, complex karyotype; HR, hazard ratio; mIGHV, mutated immunoglobulin heavy chain variable; NR, not reached; PFS, progression-free survival; uIGHV, unmutated immunoglobulin heavy chain variable.

A

PFS

Figure 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

Figure 1 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

PFS

Figure 1 · Panel C

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel C 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:extreme upward reversal
查看结果
D

PFS

Figure 1 · Panel D

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel D 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure4 个面板

Figure 3

Figure 3. Overall survival (OS). (A) All randomized patients. (B) Patients with ≥1 high prognostic risk factor including mutated TP53 , uIGHV, del(11q), and/or CK. (C) Patients with uIGHV or mIGHV. (D) Patients with or without del(11q). CK, complex karyotype; Clb, chlorambucil; mIGHV, mutated immunoglobulin heavy chain variable; PD, progressive disease; uIGHV, unmutated immunoglobulin heavy chain variable.

A

OS

Figure 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

Figure 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

OS

Figure 3 · Panel C

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

OS

Figure 3 · Panel D

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 2Figure 2. PFS by baseline characteristic subgroups. ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; IGHV, immunoglobulin heavy chain variable; LDH, lactate dehydrogenase; LDi, longest diameter; PFS, progression-free survival; ULN, upper limit of normal.
非 KM Figure
Figure 4Figure 4. Change in investigator-assessed responses over time. CR, complete response; CRi, complete response with incomplete bone marrow recovery; nPR, nodular partial response; PR, partial response; PRL, partial response with lymphocytosis; SD, stable disease.
非 KM Figure
Figure 5Figure 5. Summary of adverse events for patients treated with ibrutinib. Adverse events with prevalence ≥30% in all patients, excluding hypertension, are shown.
非 KM Figure
Figure 6Figure 6. Prevalence of adverse events of clinical interest over time. ∗Hypertension and atrial fibrillation per MedDRA preferred terms. †Major hemorrhage included serious or grade ≥3 hemorrhage, and central nervous system hemorrhage of any grade among bleeding events identified by Hemorrhage Standardized MedDRA Queries excluding laboratory terms.
非 KM Figure